CV Sciences (CVSI) AI Stock Analysis

• Market Cap: $7.37M
• Dividend Yield: N/A
• Average Volume (3M): 246.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.50
• Revenue Growth: -5.50%
• EPS Growth: 45.16%
• Country: US
• Employees: 47
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 184,263,660
• 10 Day Avg. Volume: 158,629
• 30 Day Avg. Volume: 246,649
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.04
• Enterprise Value/Revenue: 0.51
• Enterprise Value/Gross Profit: 1.10
• Enterprise Value/Ebitda: -8.50
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: $0.00 ▼(-100.00% Downside)

The overall stock score is primarily impacted by the company's weak financial performance, characterized by declining revenues and negative profit margins. While the earnings call provided some positive developments, such as improved gross margins and cost efficiencies, these are overshadowed by ongoing financial struggles. Technical analysis suggests mild upward momentum, but poor valuation metrics further weigh down the score.

CV Sciences Business Overview & Revenue Model

Company Description

CV Sciences, Inc. (CVSI) is a life sciences company based in the United States that is focused on the development and commercialization of innovative products utilizing cannabinoids. The company operates in two primary sectors: consumer products and pharmaceutical development. Its core products include a range of cannabidiol (CBD)-based dietary supplements and topicals marketed under the brand name PlusCBD Oil, as well as its pharmaceutical segment, which is engaged in the development of CBD-based therapeutics aimed at addressing various health conditions.

How the Company Makes Money

CV Sciences generates revenue primarily through the sale of its consumer products, specifically a variety of CBD-infused dietary supplements and topical products. The company has established a strong presence in the health and wellness marketplace, with its products sold through various retail channels, including health food stores, pharmacies, and online platforms. Key revenue streams include direct-to-consumer sales and wholesale distribution agreements with retailers. Additionally, CV Sciences is involved in the pharmaceutical development of CBD-based products, which could represent a significant future revenue source depending on successful clinical trials and regulatory approvals. Partnerships with retailers and collaborations in research and development further enhance its revenue potential.

CV Sciences Financial Statement Overview

Summary

CV Sciences is facing significant financial challenges, with declining revenues, negative profit margins, and cash flow issues. The balance sheet shows high leverage and low equity, posing potential financial stability risks. Overall, the company needs strategic improvements to return to profitability and improve cash flows.

Income Statement

The company has faced a declining revenue trend over the years, with a notable drop from 2019 to 2024. Gross profit margins have decreased significantly, indicating cost pressure. The EBIT and net profit margins are negative, reflecting operational inefficiencies and consistent net losses.

Balance Sheet

The company exhibits a high debt-to-equity ratio, indicating potential leverage risks. The equity ratio is low, highlighting limited funding from shareholders relative to total assets. However, there has been a reduction in total liabilities over time, which is a positive sign.

Cash Flow

Cash flow from operations has been consistently negative, pointing to cash generation challenges. Free cash flow is also negative, indicating a lack of surplus cash after capital expenditures. The operating cash flow to net income ratio suggests operational struggles.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.97M	15.71M	16.00M	16.20M	20.05M	24.43M
Gross Profit	6.96M	7.17M	7.08M	5.55M	8.62M	11.01M
EBITDA	-898.00K	-1.86M	3.85M	-5.66M	-14.00M	-21.72M
Net Income	-1.55M	-2.39M	3.10M	-8.21M	-15.55M	-22.28M
Balance Sheet
Total Assets	7.95M	7.93M	9.20M	12.74M	18.07M	30.63M
Cash, Cash Equivalents and Short-Term Investments	886.00K	454.00K	1.32M	611.00K	1.38M	4.02M
Total Debt	1.49M	779.00K	442.00K	1.53M	922.00K	7.77M
Total Liabilities	6.15M	6.13M	6.30M	13.51M	14.52M	19.41M
Stockholders Equity	1.80M	1.79M	2.90M	-777.00K	3.54M	11.21M
Cash Flow
Free Cash Flow	-187.00K	-879.00K	2.25M	-1.89M	-7.52M	-8.36M
Operating Cash Flow	-80.00K	-861.00K	2.25M	-1.89M	-7.49M	-7.30M
Investing Cash Flow	-77.00K	-28.00K	-156.00K	0.00	-35.00K	-1.06M
Financing Cash Flow	568.00K	32.00K	-1.39M	1.12M	4.37M	3.27M

CV Sciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVSI, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 53.45 is Neutral, neither overbought nor oversold. The STOCH value of 56.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CVSI.

CV Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COSM	54 Neutral	$31.63M	-1.03	-52.69%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CVSI	49 Neutral	$7.37M	-4.71	-72.00%	―	-5.50%	45.16%
YCBD	44 Neutral	$9.45M	-0.17	-33.13%	―	-7.80%	90.17%
IXHL	39 Underperform	$121.14M	―	-381.09%	―	616.67%	-22.13%
IMCC	38 Underperform	$10.60M	―	-36.94%	―	2.17%	88.34%
FLGC	38 Underperform	$12.82M	―	-230.73%	―	-24.10%	38.17%

CV Sciences Corporate Events

CV Sciences Secures $600,000 Promissory Note Agreement

On October 6, 2025, CV Sciences, Inc. entered into a note purchase agreement with an institutional investor, resulting in the issuance of a secured promissory note worth $600,000. The transaction, which closed on October 7, 2025, provided the company with net proceeds of $300,000 after deductions. The note is secured by the company’s assets and intellectual property, with repayment terms set to begin in April 2026 and a maturity date in April 2027. The agreement includes provisions for events of default, which could lead to increased liabilities for the company.

CV Sciences Amends Note Purchase Agreement

On February 12, 2025, CV Sciences, Inc. entered into a Note Purchase Agreement with an institutional investor, issuing a Secured Promissory Note for $1,600,000, with a $400,000 discount resulting in $1,200,000 received by the company. On September 12, 2025, the agreement was amended to extend the maturity date to February 12, 2027, adjust the monthly redemption amounts, and provide the investor with $150,000 in cash, maintaining the original terms otherwise.

CV Sciences’ Earnings Call: Progress Amid Challenges

CV Sciences’ latest earnings call painted a picture of both progress and challenges. The company reported significant improvements in gross margin, cash flow, and cost efficiency, alongside successful new product developments and strategic M&A integration. However, challenges such as revenue decline, regulatory issues, and a decrease in B2C revenue were noted. Despite these hurdles, the company’s positive adjusted EBITDA and improved financial metrics demonstrate progress towards profitability.

CV Sciences Reports Improved Margins and Positive EBITDA

CV Sciences, Inc. is a consumer wellness company that specializes in hemp extracts and other science-backed, natural ingredients and products, operating primarily in the nutraceutical and plant-based food sectors. The company is known for its +PlusCBD™ branded products, which are leading in the natural products market.

CV Sciences Reports Q2 2025 Financial Results

On August 13, 2025, CV Sciences announced its financial results for the second quarter of 2025, reporting a revenue of $3.6 million, a decrease from the previous year due to lower sales volume influenced by state regulatory pressures. Despite the revenue decline, the company achieved its highest gross margin since 2019 at 50.9% and reported its first positive adjusted EBITDA since 2019. The company is focusing on organic growth through new product development and mergers and acquisitions to improve profitability and shareholder value.